PT - JOURNAL ARTICLE AU - Heather J Whitaker AU - Charlotte Gower AU - Ashley D Otter AU - Ruth Simmons AU - Freja Kirsebom AU - Louise Letley AU - Catherine Quinot AU - Georgina Ireland AU - Ezra Linley AU - Sonia Ribeiro AU - Shamez Ladhani AU - Jamie Lopez-Bernal AU - Gayatri Amirthalingam AU - Mary E Ramsay AU - Kevin E Brown TI - Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off AID - 10.1101/2021.10.25.21264964 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.25.21264964 4099 - http://medrxiv.org/content/early/2021/10/26/2021.10.25.21264964.short 4100 - http://medrxiv.org/content/early/2021/10/26/2021.10.25.21264964.full AB - Serological surveillance studies sometimes use presence of anti-nucleocapsid antibody as a marker of natural SARS-CoV-2 infection. We explore seroconversion rates and antibody levels following Alpha and Delta variant infections, and vaccine breakthrough infections. We find lower seroconversion rates particularly following Alpha-variant vaccine breakthrough infections. We re-evaluate assay performance with a mix of past waned infections and recent breakthrough infections, that is relevant to current serological surveillance.Competing Interest StatementEL reports the Public Health England Vaccine Evaluation Unit performs contract research on behalf of GSK, Sanofi and Pfizer which is outside the submitted work.Funding StatementThis study was funded by Public Health EnglandAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Serosurveillance of covid-19 is undertaken under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to collect confidential patient information (www.legislation.gov.uk/uksi/2002/1438/regulation/3/made) under Sections 3.(1)(b) 3.(1)(c), 3.(1)(d)(i-iii) and 3.(3)(a). The study protocols were subject to an internal review by the Public Health England Research Ethics and Governance Group (references NR0247, NR0228) and were found to be fully compliant with all regulatory requirements. As no regulatory issues were identified, and ethical review is not a requirement for this type of work, it was decided that a full ethical review would not be necessary.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublic Health England data requests were formerly made via the Public Health England Office for Data Release. At the time of submission this service is temporarily on pause while Public Health England transitions to the UK Health Security Agency.